Internal Programs
We are currently engaged in 4 internal projects progressing from hit discovery to preclinical stage. Addressing the industry’s most challenging targets we continuously refine our platforms, expanding their capabilities to deliver impactful new therapies.
validation
Pipeline details
RAI-003 (GPCR)
We are targeting a GPCR with strong therapeutic potential for cardiovascular diseases and wound healing. Existing small molecule drugs struggle with adverse off-target effects and toxicity. To address this, we are developing peptide antagonists with distinct binding modes to eliminate safety issues.
Using our advanced pocket detection and AI-driven peptide design technologies we designed lead candidates with impressive activity and selectivity for multiple allosteric binding sites. Our current focus is optimizing permeability to enable oral delivery and to bring these novel peptides closer to clinical application.
RAI-004 (Kinase PPI)
Our focus is a transient kinase complex that regulates the genes of cytokine signaling—a highly promising target for treating inflammatory and autoimmune diseases. The lack of structural data for the functional complex made it undruggable until now.
We reconstructed the complex using our AI-powered protein-protein interface prediction technique and designed small molecule molecular glues that stabilize it in an active state. The compounds are currently in the hit-to-lead stage.
RAI-002 (Kinase)
We are targeting a non-conventional kinase isoform involved in metastatic cancers and autoimmune diseases. Previous campaigns have failed due to insufficient selectivity against another isoform that causes severe adverse effects.
Leveraging AI-enhanced molecular simulations, we identified unique transient conformational states specific to the target isoform, which allowed us to obtain first-in-class highly selective lead compounds. We are now optimizing their potency and bioavailability, advancing a once-undruggable target toward the clinics.
RAI-001 (Ion Channel)
We are addressing a mutated ion channel isoform responsible for a hereditary renal disease. Selectivity is challenging due to the presence of similar isoforms in other tissues.
Our advanced molecular modeling workflow for membrane proteins revealed the specific influence of the lipid environment on the mutant channel. By targeting the distinct conformations through AI-based virtual screening, we developed selective compounds that restore the channel’s normal function. A proof-of-concept study is currently in progress.
